Drug Profile
WW 46
Alternative Names: Parsepril; WW46Latest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Inotek Pharmaceuticals
- Class
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic complications; Inflammation
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 09 Aug 2006 Discontinued - Phase-I for Inflammation in USA (unspecified route)
- 09 Aug 2006 Discontinued - Preclinical for Diabetic complications in USA (unspecified route)